PT-141’s melanocortin inheritance
Bremelanotide borrows from alpha-MSH. The resulting medicine reaches circuits involved in sexual desire, alongside other effects that complicate the story.
From alpha-MSH to bremelanotide
PT-141 is bremelanotide, a synthetic cyclic heptapeptide: seven amino-acid building blocks arranged with a ring in the structure. Its biological starting point is alpha-melanocyte-stimulating hormone, usually shortened to alpha-MSH. It activates melanocortin receptors, particularly MC3R and MC4R in the brain. The human brain-imaging study examines that central action in women with hypoactive sexual desire disorder, or HSDD.
I’m curious about melanocortins altering desire itself. Sexual motivation is a more interesting subject than the vague promise of enhancement that so often surrounds this compound. The clinical record is also more particular.
RECONNECT questionnaire results
The two phase 3 RECONNECT trials enrolled 1,267 premenopausal women with HSDD. Over 24 weeks, bremelanotide improved both coprimary endpoints versus placebo: the integrated FSFI desire score by +0.35 and the integrated FSDS-DAO item-13 distress score by −0.33; both P<0.001.
Those are changes on questionnaires about desire and distress. I regard the statistically significant results as real evidence within the trial, while the modest numerical differences leave their practical importance unresolved for me. The figures alone cannot tell that whole story.
The FDA prescribing information confines the approval to acquired, generalized HSDD in premenopausal women. FDA approval came in June 2019. Use in men, postmenopausal women or for general sexual enhancement falls outside that approved indication.
Functional MRI in HSDD
The 2022 crossover experiment in 31 premenopausal women with HSDD used functional MRI to examine responses to erotic stimuli. MC4R agonism increased sexual desire for up to 24 hours and altered processing, including enhanced amygdala-insula functional connectivity.
The anatomical specificity interests me, although a brain image carries more apparent authority than a small experiment deserves. This helps explain a possible mechanism; the phase 3 trials address clinical efficacy.
Conditioned place preference in hamsters
The 2025 study in female Syrian hamsters tested sexual reward using conditioned place preference, a measure of an animal’s preference for a place associated with an experience. Bremelanotide did not enhance that reward measure and did not change melanocortin-receptor mRNA expression in the mesolimbic dopamine system.
The awkwardness makes this experiment valuable to me. Desire, arousal and reward are often compressed into the same promise. The animal experiment gives reason to distinguish them. Its result applies to female Syrian hamsters in that model, with limited translation to people.
Bremelanotide: nausea and cardiovascular cautions
The 52-week open-label extension enrolled 684 women. It reported sustained sexual-desire improvements and no new safety signals, with drug-related nausea in 40.4%, flushing in 20.6% and headache in 12.0%. An open-label extension has different limits from a blinded placebo comparison, including who continues into it.
The prescribing label’s cardiovascular and pigmentation cautions include transient blood-pressure increases and contraindications in uncontrolled hypertension or known cardiovascular disease. Darkening of skin, gums or mucous membranes can occur with repeated frequent use, and some changes may persist after stopping.
The biological family matters here: melanocortin receptors have roles beyond desire. Research-grade PT-141 has no regulatory verification of its identity, purity or concentration; the approved bremelanotide medicine has a specific indication and product framework.
Community accounts
Reports range from a stronger sense of wanting and greater sensitivity to no benefit despite nausea. Some men describe sexual effects during off-label use. These accounts are anecdotal, rather than clinical evidence for treating men or predicting an individual response.
I distrust predictions built from either an enthusiastic account or an unhappy one. The range itself is useful context for the sweeping claims made around sexual desire.